New publication enabled by the collaboration between UCD & Attana regarding nanoparticle interactions in human sera
Attana and University College of Dublin collaborated between 2014 and 2017 on the EU-funded project NanoClassifier. The project aimed at developing new methods for evaluation and screening of nanoparticles for therapeutic applications. In a new joint scientific publication some of these methods are published. This means that Attana strenghten our offering towards customer working with nanoparticles for therapeutic nanoparticles.
Proteins and other biomolecules in human biological fluids interact with the surfaces of nanoparticles. These interactions generate a coating (corona) around the nanoparticles which is the nanoparticles interface in the human body. Attana´s technology was used to characterized corona coated nanoparticles interactions with different biomolecules. The obtained information is a valuable tool to optimize nanoparticles for therapeutic applications and to improve the predictability of in vivo performance of the nanoparticles. During the EU-project several different assays have been developed based on Attana’s technology and some of the results have now been published in the journal Nanoscale. In the paper, accessible functional epitopes of transferrin-coated nanoparticles are quantified and their number is correlated to differences in nanoparticle size and functionalization. The label free in flow target recognition pushes the assays into a more in vivo-like scenario than previous technologies. The assays are applicable to a wide array of nanoparticles and consequently hold the potential to become a standard technique for the classification of nanoparticles based on their biological external functionality.
For more information, please contact:
Teodor Aastrup, CEO Attana AB
e-mail: teodor.aastrup@attana.com
tel: + 46 8 674 57 00
The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share prices, but is of general interest for the shareholders and hence should be communicated.
Attana was founded in 2002 with the vision of in-vitro characterization of molecular interactions mimicking in-vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays. Attana’s products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about Attana’s contract research services and our label free cell-based biosensors, please visit www.attana.com or contact sales@attana.com.
